FDA Panel Unanimously Approves Two New Hep C drugs
Amid all the angst regarding the high costs of drug discovery, it is refreshing to see two new drugs for Hepatitis C approved by FDA advisory panels. In the past two days the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously approved Merck’s investigational medicine VICTRELIS™ (boceprevir) and Vertex’s telaprevir. (Disclaimer: CDD CEO Barry Bunin has been a Vertex Shareholder since the telepravir phase 2 results were announced).
As a community of scientists, clinicians, executives, regulators, patients, and people, we can take a moment to smile and appreciate the progress. The prognosis is now brighter for those with Hepatitis C. And given the strong pipelines, new targets, and large need, it seems that the Hep C combination therapies will only get better in the near future.